Corbus Pharma

10/16/2026

We believe CRB-913 is positioned as a transformative therapeutic option, potentially reducing the severe health risks associated with and enabling people to lead healthier, more active lives. Learn about the science behind CRB-913: https://bit.ly/40Lts1n

10/01/2026

TEMPO-1 is a randomized controlled study (n=250) designed to evaluate the efficacy and safety of CRB-701 compared with investigator's choice of capecitabine, cetuximab or docetaxel. FDA approval for the study to proceed was supported by results from Corbus' ongoing Phase 1/2 clinical study of CRB-701, presented at the 2026 ASCO Annual Meeting. In patients with 2L+ OPSCC treated at the 3.6 mg/kg dose, CRB-701 achieved a confirmed ORR of 42.9%, with a median duration of response of 6.3 months and a median progression-free survival of 5.6 months (ongoing). Learn more: https://bit.ly/47ruO4M

09/30/2026

"For patients with recurrent or metastatic head and neck cancer, there remains a significant unmet need for new treatment options after progression on frontline therapy," said Dr. Cesar A. Perez, Director of the Drug Development Unit at Sarah Cannon Research Institute at Florida Cancer Specialists & Research Institute in Orlando, FL, and Principal Investigator of the TEMPO-1 study. Learn more: https://bit.ly/47ruO4M

09/29/2026

"Dosing the first patient in our TEMPO-1 trial marks an important step in advancing CRB-701 as a potentially novel targeted therapeutic for those impacted by OPSCC," said Leonardo Nicacio, M.D., Chief Medical Officer of Corbus. Read more about the TEMPO-1 registrational study: https://bit.ly/47ruO4M

09/29/2026

Corbus today announced that the first patient has been dosed in its TEMPO-1 registrational study of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate (ADC), in second-line and beyond (2L+) oropharyngeal squamous cell carcinoma (OPSCC). OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000 patients eligible for treatment annually. For details: https://bit.ly/47ruO4M

09/16/2026

ICYMI - Corbus hosted a webcast to discuss the positive topline data for CANYON-1, a Phase 1b study of CRB-913 for the treatment of obesity. Harold Bays, M.D., an investigator for the study, joined Corbus CEO Yuval Cohen, Ph.D. to provide insights. Listen to the replay here: https://bit.ly/4yv5nLb

09/15/2026

CRB-913 demonstrated rapid, statistically significant and clinically meaningful weight loss at all dose levels in the CANYON-1 Phase 1b trial, with no evidence of plateauing at any of the doses. All participants who completed the study and received CRB-913 at the 60 mg dose lost weight, with 44.4% losing at least 5.0% from baseline and the highest recorded weight loss reaching 13.4%. Learn more: https://bit.ly/46iIA9z

09/14/2026

Financial Times featured Corbus' positive topline data from the CANYON-1 Phase 1b trial for CRB-913, our once-daily oral CB1 inverse agonist, noting that weight loss was shown to be comparable to leading oral GLP-1 therapies with markedly less nausea, vomiting, and constipation, in a trial of more than 200 people living with obesity.

"This initial data seems to indicate that our CB1-targeting drug has comparable weight-loss efficacy to the commercially available oral GLP-1s while delivering a very differentiated GI tolerability profile with markedly less vomiting and nausea," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Read the full FT article here: https://bit.ly/4cHOVPn

Participants lost weight without gastrointestinal problems associated with GLP-1 medicines

09/14/2026

Our CEO, Yuval Cohen, Ph.D. comments on the positive topline data from the CANYON-1 study of daily oral CRB-913 for the treatment of obesity. The data have been selected for a late-breaking presentation at ObesityWeek® 2026. For details: https://bit.ly/46iIA9z

09/14/2026

Event Reminder: Tune in today, September 14 at 8:00 a.m. EDT for a conference call featuring Corbus CEO Yuval Cohen, Ph.D., and Harold Bays, M.D., who will discuss topline data for CANYON-1, a Phase 1b study of CRB-913 for the treatment of obesity. Register here: https://bit.ly/4yv5nLb